On paper, this is a straightforward upgrade: discretion out, a public formula in. But before getting into the specifics, it’s worth zooming out on where this proposal is coming from, and what the market has been rewarding from digital asset companies over the past year.
The paradigm shift, and why I’m skeptical of it
There’s been a clear shift in how the market values tokens, and Hyperliquid is a big part of why. Hyperliquid made a programmatic ~99% buyback of revenue a core part of its business model, with that supply effectively treated as burned.
HYPE is arguably one of the biggest success stories this industry has produced, from the growth of the exchange itself to the price discovery it’s enabled across equities, commodities, and even the largest IPO ever (SPCX). It’s an unprecedented company with an unprecedented value-sharing mechanism, returning essentially all value creation directly to HYPE holders.
Unsurprisingly, a lot of digital asset companies have tried to copy that playbook, hoping the market rewards them with the same repricing. Some of that pressure is genuine strategy; some of it is self-interested, investors sitting on unrealized losses, or simply wanting exit liquidity, have an obvious incentive to push for buybacks regardless of whether it’s the right capital allocation call for the business. You can’t lift a revenue-sharing playbook from a business like Hyperliquid and assume it transfers cleanly to one with a fundamentally different growth profile and moat, especially one that hasn’t yet proven itself the way Hyperliquid has.
My own view: as long as token holders have real rights, to revenue, brand, IP, etc., with no external equity entity capturing those same cash flows (Maple doesn’t have any equity entity on top), there’s already value in simply owning the token; layering buybacks on top of a token with no attached rights is, at best, a way to manufacture the appearance of value accrual. This is fundamentally a capital allocation decision, and I’d rather see a still-scaling company reinvest close to 100% of cash flow into growth, widening the moat, building out every meaningful business line, than start returning capital before its market position is settled. I’d rather wait years for buybacks once the business has actually won than see a young company redirect cash from growth to chase a market narrative.
That said, this is what the market has rewarded over the past year, and Maple’s team has to operate within that reality, not the one I’d prefer. With that context in mind, here’s where I land on MIP-021 specifically.
What’s positive about MIP-021
- Replacing discretionary allocation with a public, rules-based formula is a governance improvement. Buyback intensity is no longer a closed-door judgment call, it’s a number anyone can derive from the Transparency page or Dune once monthly net revenue is published.
- The tiered structure has sound logic. Buyback intensity scales with the health of the business instead of staying fixed regardless of performance, better aligning capital return with the strength of the quarter.
- Management is listening. Investors have been asking for a more programmatic, less discretionary buyback, and within two days of the proposal going up the team clarified the revenue definition and committed to a hard execution deadline (15th of the following month), the two most concrete asks raised in the thread. The six-month sunset means a miscalibrated version doesn’t get locked in indefinitely.
- The Transparency page commitment is a step forward, real visibility into Maple’s books.
- Bought-back SYRUP isn’t walled off from the rest of the SSF, and we think that’s the right call. The SSF’s mandate is unchanged from MIP-019: the fund exists to pursue strategic opportunities, support token liquidity, and hold capital reserves and buybacks, all under one umbrella, and nothing in MIP-021 carves out distinct treatment for tokens acquired specifically through this program, they read as fungible with the SSF’s other holdings from day one. Given our own preference for capital to stay available for growth rather than being permanently retired, we’d rather Maple keep the flexibility to redeploy that capital toward strategic opportunities when the opportunity cost favors it, instead of committing to a pure, irreversible buyback. It means a “buyback” here reads more like working treasury capital denominated in SYRUP than a permanent supply reduction, which, on capital-allocation grounds, is actually the outcome we’d prefer.
What’s negative about MIP-021
-
We’d rather see a larger share of protocol income reinvested into growth than allocated to buybacks. This is a capital allocation view, not a market observation: even at the current tiers, up to 30% of monthly income going to buybacks is capital that could otherwise fund M&A, new business lines, or emerging opportunities for a business that’s still scaling. This is our own preference, and should be read as distinct from the market’s expectations around the prior framework, addressed below.
That said, we’re encouraged to see that bought-back SYRUP won’t be burned or held out of circulating supply — it can instead be put to work driving further growth in earnings.
-
Calibration versus the prior framework. Several commenters in the thread assumed the prior regime ran a flat 25% buyback rate, and we noted MIP-021’s tiers could realistically undershoot that near-term. On closer look, the prior 25% SSF allocation covered buybacks and other uses, not buybacks alone , so it was never a pure buyback rate, and the “step back” framing doesn’t hold up as stated. What we’d still flag: on a forward-looking basis, Maple’s $50M ARR target by year-end works out to roughly $4.2M/month, comfortably above the $2.0M threshold, putting the protocol in the 30% tier, a genuinely strong outcome if the growth trajectory holds, independent of how the prior framework is characterized.
-
Revenue cyclicality. We’d originally framed Maple’s revenue as cyclical with the broader market, and that’s probably too strong a word: originations grew over the past year even as the broader market was negative, which shows real resilience and argues against a tight, mechanical cyclical relationship. That said, we’d still expect improved market conditions to lift borrowing demand, borrowing rates, and collateral yield together, which flows through to Maple’s own revenue, and those same conditions are also the ones most likely to support a higher valuation multiple for SYRUP, both through broader market sentiment and through the market reading strong revenue prints bullishly. Put together, the highest-revenue months, the ones most likely to push Maple into the 30% tier, are also, on average, the months where SYRUP costs more. The mechanism doesn’t need revenue and price to move in lockstep for this to hold; it just needs them to be correlated often enough that, over time, more capital gets deployed at higher average multiples than a valuation-agnostic schedule would produce. It’s a genuine trade-off without a clean answer, and where holders land on it will largely come down to preference between predictability and price-sensitivity.
-
Income statement reporting. NIM is already published on the Transparency page, which covers part of what we were asking for. The more precise gap is full operating profitability, opex, SG&A, and bottom-line margin, rather than interest margin alone, since that’s what’s actually needed to judge whether committing up to 30% of income to buybacks is a good use of capital relative to the alternatives.
Conclusion and ways to improve the proposal from GLC’s perspective
We think this is a step forward for Maple and its various stakeholders. The team has been listening to investor and community feedback, and is operating within an environment that currently rewards buybacks as a way to build investor confidence — in an industry where the split between token holder rights and equity holder rights remains a major, unresolved topic of debate, as we’ve recently seen play out with $VVV.
With this proposal, Maple is trying to get the best of both worlds: giving investors what they’ve been asking for, a more programmatic buyback that supports valuation, while retaining the flexibility to redeploy that capital toward growth opportunities as they arise.
First suggestion would be Full operating profitability reporting, beyond NIM. NIM is already published; adding opex, SG&A, and bottom-line margin alongside it would let holders judge capital allocation decisions on a fully loaded basis, not just gross margin.
Second and most important suggestion at this stage would be to give the team some runway before executing each buyback, a six-month window, for example, within which the team can buy SYRUP at the most favorable price available, building a long-term reserve that, if executed well, ultimately provides Maple with meaningfully more capital than an immediate, mechanical execution schedule would. We think forcing immediate execution each month will simply push Maple to buy SYRUP at higher valuation multiples on average, whereas granting that flexibility shouldn’t change market perception at all—buybacks are already priced in—while giving the team room to optimize execution and generate additional value from the same allocated capital.